Liver‐Related Late Effects in Long‐Term Survivors of High‐Risk Neuroblastoma: Insights From a Comprehensive Prospective Follow‐Up Study
Pediatric Blood & Cancer · 2026
DOI: 10.1002/1545-5017.70127 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Angelo Zarfati und 12 weiteren Autor:innen. Beteiligte Einrichtung: Surgical Oncology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Neuroblastoma, Cancer Survivors, Liver Diseases. Die Arbeit nennt 56 Literaturangaben.
Abstract (Originalsprache)
Background
Therapeutic advances in pediatric oncology have significantly improved overall survival, with a higher incidence of long‐term adverse effects and sequelae. Among pediatric cancer survivors, the highest incidence of hepatic lesions has been observed in those previously treated for high‐risk neuroblastoma (HRNB). While hepatic nodules in these patients historically raised concern for tumor locations, recent attention has shifted toward non‐tumoral, late‐onset hepatic sequelae.
Methods
In this study, we retrospectively reviewed long‐term liver outcomes from an institutional perspective follow‐up protocol, including long‐term HRNB survivors (>5 years from diagnosis) treated between 1996 and 2018 at a tertiary pediatric center.
Results
A total of 47 patients were included, with a median follow‐up of 11.1 years. Liver parenchyma was normal in 11 (23%) patients throughout the whole follow‐up period. Diffuse parenchymal inhomogeneity was observed in 36 patients out of 47 (76%). Out of 36 patients, 16 showed a stable, diffuse, non‐nodular alteration of the liver during the whole follow‐up period, while in seven patients, the liver involvement completely regressed after a median of 2.8 years. Moreover, 13 out of 36 patients (36%) with diffuse parenchymal inhomogeneity developed nodular lesions after a median of 7.7 years from diagnosis and 1.7 years from the onset of parenchymal alterations. Alpha‐fetoprotein levels were normal in all patients.
Conclusions
A structured, integrated, multidisciplinary follow‐up program revealed an unexpectedly high prevalence of hepatic abnormalities on imaging. Further studies are needed to define the long‐term risk of developing liver complications, both in terms of malignancy and functional impairment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Surgical Oncology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
- University of Tor Vergata, Rome, Italy.
- Radiology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
- Department of Life and Health Professions Sciences, Link Campus University, Rome, Italy.
- Onco-Hematology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
- Metabolic Diseases and Hepatology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
ORCID-Profile: Angelo Zarfati, Giorgia Romano, Alessandro Crocoli, Giorgio Persano, Giovanni Rollo, Maria Antonietta De Ioris
Zitieren
APA
Zarfati, A., Romano, G., Crocoli, A., Monti, L., Persano, G., Grimaldi, P., Rollo, G., Soglia, G., Di Giannatale, A., Serra, A., Pietrobattista, A., De Ioris, M. A., & Grimaldi, C. (2026). Liver‐Related Late Effects in Long‐Term Survivors of High‐Risk Neuroblastoma: Insights From a Comprehensive Prospective Follow‐Up Study. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70127
Vancouver
Zarfati A, Romano G, Crocoli A, Monti L, Persano G, Grimaldi P, et al. Liver‐Related Late Effects in Long‐Term Survivors of High‐Risk Neuroblastoma: Insights From a Comprehensive Prospective Follow‐Up Study. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70127
BibTeX
@article{Zarfati2026,
author = {Zarfati, Angelo and Romano, Giorgia and Crocoli, Alessandro and Monti, Lidia and Persano, Giorgio and Grimaldi, Piercesare and Rollo, Giovanni and Soglia, Giovanna and Di Giannatale, Angela and Serra, Annalisa and Pietrobattista, Andrea and De Ioris, Maria Antonietta and Grimaldi, Chiara},
title = {Liver‐Related Late Effects in Long‐Term Survivors of High‐Risk Neuroblastoma: Insights From a Comprehensive Prospective Follow‐Up Study},
journal = {Pediatric Blood & Cancer},
year = {2026},
doi = {10.1002/1545-5017.70127}
}
EUVIMED